AU1671699A - Pharmaceutical combination of a cyclooxygenase-2 inhibitor - Google Patents

Pharmaceutical combination of a cyclooxygenase-2 inhibitor

Info

Publication number
AU1671699A
AU1671699A AU16716/99A AU1671699A AU1671699A AU 1671699 A AU1671699 A AU 1671699A AU 16716/99 A AU16716/99 A AU 16716/99A AU 1671699 A AU1671699 A AU 1671699A AU 1671699 A AU1671699 A AU 1671699A
Authority
AU
Australia
Prior art keywords
cyclooxygenase
inhibitor
pharmaceutical combination
pharmaceutical
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16716/99A
Inventor
Francois Camborde
Alix Cloarec
Eric Nicolai
Jean-Marie Teulon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UPSA SAS
Original Assignee
UNION PHARMA SCIENT APPL
UPSA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNION PHARMA SCIENT APPL, UPSA SAS filed Critical UNION PHARMA SCIENT APPL
Publication of AU1671699A publication Critical patent/AU1671699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU16716/99A 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor Abandoned AU1671699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714428A FR2771005B1 (en) 1997-11-18 1997-11-18 NEW PHARMACEUTICAL ASSOCIATION WITH ANALGESIC ACTIVITY
FR9714428 1997-11-18
PCT/EP1998/007537 WO1999025382A1 (en) 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
AU1671699A true AU1671699A (en) 1999-06-07

Family

ID=9513481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16716/99A Abandoned AU1671699A (en) 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor

Country Status (3)

Country Link
AU (1) AU1671699A (en)
FR (1) FR2771005B1 (en)
WO (1) WO1999025382A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
WO2000029023A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO1996013483A1 (en) * 1994-10-27 1996-05-09 Merck Frosst Canada Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
SK133297A3 (en) * 1995-04-04 1998-07-08 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, pharmaceutical composition containing same and their use
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
UA57002C2 (en) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Also Published As

Publication number Publication date
FR2771005A1 (en) 1999-05-21
WO1999025382A1 (en) 1999-05-27
FR2771005B1 (en) 2002-06-07

Similar Documents

Publication Publication Date Title
AU9692898A (en) Potentiation of pharmaceuticals
IL150352A0 (en) Sustained-release formulation of a cyclooxygenase-2 inhibitor
AU1589999A (en) Annular piezoelectric transformer
AU5387898A (en) Pharmaceutical agents
AU6904896A (en) Pharmaceutical compounds
AU8638298A (en) A piece of jewellery
AU5685498A (en) A device for relative displacement of two elements
AU2719597A (en) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
AU8591898A (en) Pharmaceutical compounds
AU1668299A (en) Stabilised cyanoacrylate adhesives
ZA984966B (en) Crystal modification of a pharmaceutical agent
AU4479096A (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AU1703799A (en) Cyclooxygenase-2 inhibition
AU6739896A (en) Genetic transformation using a parp inhibitor
AU8673598A (en) Neuraminidase inhibitors
AU9640698A (en) Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate
AU6422298A (en) Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AU4641097A (en) New pharmaceutical parenteral formulation of a thrombin inhibitor
AU2088399A (en) Brefeldin a derivatives
AUPP076797A0 (en) Phospholipase inhibitor
AU1671699A (en) Pharmaceutical combination of a cyclooxygenase-2 inhibitor
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
AU6049796A (en) Lysyloxidase inhibitors
AU8817398A (en) Method of drug selection
AUPO695497A0 (en) End of line pipeliner

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase